Filing Flows › Health Care › Xenon Pharmaceuticals (XENE)
Xenon Pharmaceuticals (XENE) earnings and revenue breakdown
Latest: Q1 2025 · 10-Q filed May 12, 2025 · Xenon Pharmaceuticals (XENE) Q1 2025 earnings results →
Q1 2025 867¢ of every $1 of revenue lost · operating margin -969.8%
Xenon Pharmaceuticals made $7.5M in Q1 2025. Operating margin -969.8%, net loss $65.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed May 12, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $7.5M in Q1 2025.
Operating costs exceeded revenue by $72.7M, an operating margin of -969.8%. The quarter ended with a net loss of $65.0M.
Operating cash flow was −$61.7M. Non-cash charges added back $659K of depreciation and amortization and $12.2M of share-based compensation. Working capital and other items used $9.4M. Capital expenditures of $43K exceeded it, leaving free cash flow of −$61.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 2025 | 10-Q | May 12, 2025 | $7.5M | — | -969.8% | −$65.0M | −$61.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
About Xenon Pharmaceuticals
We are a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. We are advancing a differentiated product pipeline led by our investigational candidate, azetukalner, which is being studied in multiple Phase 3 studies in epilepsy, major depressive disorder, or MDD, and bipolar depression, or BPD. Our early-stage pipeline includes Kv7 potassium channel openers and Nav sodium channel modulators being advanced for select high‑need indications, including pain.
In its own words, from its 10-K, filed Feb 26, 2026.
Xenon Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -969.8% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| XENE Xenon Pharmaceuticals | Q1 2025 | $7.5M | — | -969.8% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Xenon Pharmaceuticals 10-Q on SEC EDGAR · CIK 1582313 · Pharmaceutical Preparations
13F: who owns XENE and who is buying
More on XENE
- How Xenon Pharmaceuticals makes money: revenue by segment
- Xenon Pharmaceuticals next earnings date and what analysts expect
- Xenon Pharmaceuticals stock forecast, price target and fair value
- Who owns Xenon Pharmaceuticals stock: holders, funds and Congress trades
- Is Xenon Pharmaceuticals a takeover target? LBO and rumors
- Xenon Pharmaceuticals recalls, complaints and regulation
History
Every quarter: Q1 2025 results